C4 Therapeutics, Inc.

Single-Patient EA Policies/Criteria On our website, both physicians and patients may explore information about our investigational agents. Our EAP policy is described below. Several factors consistent with the FDA and other regulatory agencies’ guidelines, are essential when considering expanded access requests: Given the early stage of our development program, we believe that participation in our clinical trial is the most appropriate way to access our investigational therapy. Therefore, we are not currently making our investigational product available through an expanded access program. If you have additional questions, please speak with your physician or have your physician contact clinicaltrials@c4therapeutics.com . We anticipate acknowledging receipt of requests sent to this email within five business days. In line with the 21st Century Cures Act, C4 Therapeutics, Inc may revise this policy at any time. This website and policy will be updated with a hyperlink or other reference to the expanded access record on clinicaltrials.gov if such record becomes active.